Context Therapeutics is a clinical-stage company developing T cell engager antibodies for solid tumors, led by CTIM-76 for platinum-resistant ovarian cancer; none is approved.
Context's case rests on CTIM-76, a T cell engager that targets Claudin 6. Weekly dosing produced a 29% confirmed response rate in 9 evaluable patients with platinum-resistant ovarian cancer, with only low-grade CRS. Context is now testing every-three-week dosing, with initial data due in the second quarter of 2027. In August it stopped developing CT-95 to focus on CTIM-76 and CT-202. Cash of $43.0 million at June 30 is expected to last into the fourth quarter of 2027.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Every-three-week dosing supports a registration path
Does every-three-week CTIM-76 match the 29% response rate seen with weekly dosing, with low CRS?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Context narrowed to CTIM-76 and CT-202; every-three-week CTIM-76 data are due in Q2 2027
CTIM-76's 29% ORR in PROC sets up Q3W dosing data as the pivot point for whether this TCE can compete in a crowded late-line ovarian market
CTIM-76's Phase 1 data in platinum-resistant ovarian cancer will determine whether Context's T-cell engager strategy can compete in a crowded late-line solid tumor field
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Breast and gynecologic cancers, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
19 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.